Andrew Denker

Andrew Denker is currently serving as the Chief Medical Officer at Flamingo Therapeutics. Prior to this role, Andrew held positions as Vice President Early Development at ElevateBio, Vice President and Global Project Team Lead as well as Executive Director Global Medical Sciences at Alexion Pharmaceuticals, Inc. Andrew's extensive experience also includes roles at Merck, where Andrew served as Executive Director in Oncology Clinical Development and Senior Director in Clinical Development. Andrew Denker holds an MD and PhD in Biochemistry and Molecular Biology from Jefferson Health, and an AB in Molecular Biology from Princeton University.